<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney function and non-kidney solid organ transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney function and non-kidney solid organ transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney function and non-kidney solid organ transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roy D Bloom, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 09, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>As outcomes following non-kidney solid organ transplantation have improved, chronic kidney disease (CKD) has become an increasingly prevalent complication in this population [<a href="#rid1">1-3</a>]. CKD occurs despite advancements in immunosuppression and perioperative management, as well as attention to cardiovascular risk factors and infectious complications [<a href="#rid4">4</a>].</p><p>The development of CKD is associated with enhanced morbidity and mortality [<a href="#rid5">5</a>].</p><p>Issues relating to kidney function following non-kidney solid organ transplantation, including the evaluation of kidney function prior to non-kidney organ transplantation, are presented in this topic review. A review of calcineurin inhibitor nephrotoxicity is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION OF KIDNEY FUNCTION PRIOR TO NON-KIDNEY ORGAN TRANSPLANT</span><span class="headingEndMark"> — </span>As a general rule, the preoperative evaluation of kidney function in candidates for non-kidney solid organ transplantation should focus on an assessment of prior kidney injury and function impairment (including duration and prior reversibility), the current level of kidney function, and the likelihood and rate of progression after solid organ transplantation. Patients who are likely to have stage 4 or stage 5 chronic kidney disease (CKD) early after non-kidney organ transplant or those with established primary kidney disease that is likely to progress rapidly (thereby requiring chronic kidney replacement therapy or kidney transplant listing shortly after transplant) should be listed for combined organ transplant. In an era of ever-increasing organ shortage and longer waiting times for kidneys, combined non-kidney and kidney organ transplantation should be considered very judiciously. Until recently, the absence of standardized medical criteria has largely resulted in transplant centers arbitrarily deciding on the indication for kidney transplantation in conjunction with a non-kidney organ.</p><p>In 2016, the United Network for Organ Sharing (UNOS) approved a new policy that formalized the allocation of simultaneous liver-kidney (SLK) transplants, which went into effect in August 2017 [<a href="#rid6">6</a>]. Similar formal criteria have not yet been established for combined heart-kidney or lung-kidney transplantation. (See <a class="local">'Approach in liver transplant candidates'</a> below.)</p><p>The vast majority of patients with normal or mild impairment in kidney function should receive a non-kidney solid organ transplant alone.</p><p class="headingAnchor" id="H3665722177"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of kidney function in non-kidney solid organ transplant candidates typically includes the following [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of prior kidney function over at least the past 90 days</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of current kidney function</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis with microscopy</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary electrolytes and osmolality</p><p class="bulletIndent1"><span class="glyph">●</span>24-hour urine collection for protein and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging studies of the kidneys</p><p></p><p>Based upon findings from this initial evaluation, a kidney biopsy may be required. (See <a class="local">'Kidney biopsy'</a> below.)</p><p class="headingAnchor" id="H1203835009"><span class="h3">Assessment of prior kidney function</span><span class="headingEndMark"> — </span>The level of kidney function and duration of kidney disease prior to organ transplantation is an important risk factor for posttransplant CKD. We determine the baseline serum creatinine concentration and the presence or absence of proteinuria in at least the three months prior to the current evaluation. Acute kidney injury (AKI) may be primarily due to deterioration in underlying heart, lung, or liver disease and is frequently compromised by poor effective circulating volume (eg, cardiorenal syndrome or hepatorenal syndrome). In these situations, kidney function may improve after replacement of the non-kidney failing organ.</p><p class="headingAnchor" id="H3602207761"><span class="h3">Measurement of current kidney function</span><span class="headingEndMark"> — </span>We routinely evaluate current kidney function through the use of the four-variable Modification of Diet in Renal Disease (MDRD) formula to estimate GFR. However, an alternative option is measurement of 24 hour urine creatinine clearance.</p><p>In general, methods of estimating GFR through the use of creatinine-based formulas lack precision, but they may provide a better assessment than serum creatinine alone in this patient population. The serum creatinine level may overestimate GFR, especially in patients with advanced liver disease or advanced heart failure, who frequently have poor nutritional status, low muscle mass, weight loss, and edema [<a href="#rid8">8,9</a>]. Since the pretransplant level of kidney function is one of the main predictors of kidney function following non-kidney solid organ transplantation, failure to accurately estimate GFR by the use of serum creatinine alone may result in unrealistic expectations of what kidney function will be after the transplant. The MDRD and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations have been shown to perform better than other creatinine-based estimating equations in solid organ transplant recipients [<a href="#rid10">10</a>]. More accurate methods of estimating GFR that rely on the renal clearance of various radionuclide markers (eg, 125I-labeled iothalamate) are limited by availability, cost, and radiation exposure [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Limitations of the methods available to estimate GFR among transplant candidates are illustrated by the following studies [<a href="#rid8">8,12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a large study of 1447 liver transplant candidates, serum creatinine-based GFR estimation equations (MDRD, Cockroft-Gault, and Nankivell formulas) were compared with 125I-labeled iothalamate GFR measurements performed before and after transplantation [<a href="#rid8">8</a>]. The mean pretransplant creatinine was 1.15 mg/dL, and the mean iothalamate GFR was 91 mL/min. Of the formulas, the MDRD estimates correlated best with GFR, although only 66 percent of estimates were within 30 percent of the measured GFR. When patients were divided into two groups according to GFR greater or less than 40 mL/min, all the formulas overestimated GFR in the patients with poor function (GFR &lt;40 mL/min), while the formulas underestimated GFR in patients with better function (GFR &gt;40 mL/min). (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 300 liver transplant candidates, serum creatinine-based GFR estimation equations (four- and six-variable MDRD, CKD-EPI) were compared with <a class="drug drug_general" data-topicid="8927" href="/z/d/drug information/8927.html" rel="external">iohexol</a> clearance as the gold-standard measure of GFR [<a href="#rid13">13</a>]. The six-variable MDRD formula had superior accuracy compared with the four-variable MDRD formula as well as with the CKD-EPI equations in identifying patients with GFR &lt;30 mL/min. However, the six-variable MDRD underestimated kidney function in patients with GFR &gt;30 mL/min.</p><p></p><p>A 24-hour collection for creatinine clearance is also likely to overestimate GFR in patients with kidney disease as the contribution of tubular secretion of creatinine to total clearance is increased in this subset of patients. This was best shown in a systematic review and meta-analysis of seven studies of 193 patients with liver cirrhosis in which the measured creatinine clearance was compared with true GFR (as assessed by inulin clearance) [<a href="#rid14">14</a>]. Overall, the measured creatinine clearance overestimated inulin clearance by a mean of 13 mL/min per 1.73 m<sup>2</sup>, with the overestimation being highest in those with the lowest true GFRs. Among those with inulin clearance of less than 30 mL/min per 1.73 m<sup>2</sup> (stage 4 and 5 CKD), the measured creatinine clearance correctly classified 64 percent of patients, incorrectly classified 23 percent of patients as having GFRs between 30 to 59 mL/min per 1.73 m<sup>2</sup>, and incorrectly classified 14 percent as having GFRs ≥60 mL/min per 1.73 m<sup>2</sup>.</p><p>Some, but not all, studies suggest that cystatin C level measurement (where available) is a more sensitive indicator of kidney function than the serum creatinine concentration in patients with liver or heart disease [<a href="#rid15">15-19</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 65 cirrhotic patients comparing cystatin C-based formulas with creatinine-based equations, using 51Cr-labeled EDTA-measured GFR as the reference, cystatin C-based formulas were no better than creatinine-based equations at estimating GFR [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 202 liver transplant candidates, the Chronic CKD-EPI equation (CKD-Epi-CystC) performed better with less bias and more precision than all the creatinine-based equations, although the study was limited by a small number of patients with GFR &lt;60 mL/min per 1.73 m<sup>2</sup> and Model for End-Stage Liver Disease (MELD) scores &gt;15 [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H1230657688"><span class="h3">Urine studies</span><span class="headingEndMark"> — </span>The following urine studies should be performed:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis – A urinalysis should be performed to assess the presence of microscopic hematuria and proteinuria. (See  <a class="medical medical_review" href="/z/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine electrolytes and osmolality - Urine electrolytes are useful for assessing the effective volume status of patients and renal concentrating ability of patients with abnormal kidney function. We obtain urinary sodium or fractional excretion of sodium, which may also provide important diagnostic information for hepatorenal syndrome in patients awaiting liver transplantation, or for cardiorenal syndrome in heart transplant candidates. Such conditions represent situations in which the renal hemodynamic state usually improves with appropriate organ transplantation and where kidney function may be expected to likewise undergo some degree of recovery. (See  <a class="medical medical_review" href="/z/d/html/7219.html" rel="external">"Fractional excretion of sodium, urea, and other molecules in acute kidney injury"</a> and  <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-four-hour urine collection – A 24-hour urine collection should be obtained for quantification of proteinuria. The presence of significant proteinuria (&gt;500 mg/24 hours) should prompt a full evaluation to elucidate the nature and the prognosis of the kidney disease. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3950792947"><span class="h3">Kidney imaging</span><span class="headingEndMark"> — </span>An imaging study (computed tomography [CT] scan, magnetic resonance imaging [MRI], or ultrasound) of the kidneys should be performed to exclude obstruction, stone disease, or cysts, as well as to evaluate kidney size and cortical thickness [<a href="#rid20">20</a>]. A kidney ultrasound can also provide information regarding echogenicity. Echogenic kidneys less than 10 cm in length usually indicate irreversible.</p><p class="headingAnchor" id="H551811609"><span class="h2">Kidney biopsy</span><span class="headingEndMark"> — </span>Kidney biopsy may be considered when urinary abnormalities such as microscopic hematuria, proteinuria, and red blood cell casts are detected, or where the etiology of kidney dysfunction is not apparent from routine clinical data [<a href="#rid21">21,22</a>]. As an example, a kidney biopsy may help to differentiate intrinsic kidney disease from renal hypoperfusion.</p><p>Biopsy may be performed percutaneously under ultrasound or CT guidance if the patient condition allows, but it may be complicated by bleeding. In a retrospective series in which 44 liver transplant candidates with abnormal kidney function of undetermined etiology for less than eight weeks duration underwent percutaneous kidney biopsy, bleeding complications requiring at least one unit of blood occurred in 30 percent of patients [<a href="#rid23">23</a>]. More than half of the complications were major, defined by the requirement for two or more units of blood and/or intervention. By multivariable analysis, only International Normalized Ratio (INR) at the time of biopsy was an independent predictor of complication. A transjugular kidney biopsy should therefore be considered in patients with severe coagulopathy or on mechanical ventilation in whom a percutaneous approach may not be feasible or safe [<a href="#rid24">24-26</a>] (see  <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">"The kidney biopsy"</a>). In a series of 30 heart transplant candidates that underwent kidney biopsy for an eGFR &lt;40 mL/min per 1.73 m<sup>2</sup> or proteinuria &gt;500 mg/day, only one patient had bleeding to the point of needing a blood transfusion or intervention to stop the bleeding [<a href="#rid27">27</a>].</p><p>Glomerulonephritis may be clinically silent in liver transplant candidates, especially those with hepatitis C infection. A single-center study, for example, reported the kidney histology and kidney outcomes of 30 liver transplant patients with hepatitis C virus (HCV) infection who underwent liver transplantation alone and had a kidney biopsy at the time of transplantation [<a href="#rid28">28</a>]. Immune-complex glomerulonephritis was noted in 25 patients, 12 with membranoproliferative glomerulonephritis, seven with IgA nephropathy, and six with mesangial glomerulonephritis; only one patient had a normal kidney biopsy. Of this cohort, 10 patients had normal serum creatinine levels, normal urinalysis results, and normal quantitative proteinuria. For five others, the only kidney abnormality was an increased serum creatinine level. No patient had cryoglobulins in the blood or kidney. This study, together with others [<a href="#rid23">23,27</a>], highlights the lack of correlation between clinical parameters and kidney histology in patients with decompensated liver or heart disease.</p><p>Whether post-liver or -heart transplant CKD progression is better predicted prior to surgery by kidney histological damage, kidney function, or clinical judgment, taking into account the entire clinical picture, has not been established.</p><p class="headingAnchor" id="H3"><span class="h2">Approach in liver transplant candidates</span><span class="headingEndMark"> — </span>Since the introduction in 2002 of the MELD scoring system, which takes creatinine into account in prioritizing patients for liver transplantation, the proportion of liver recipients with impaired kidney function at the time of transplant has increased [<a href="#rid29">29</a>]. In parallel, the proportion of all liver transplants done as simultaneous liver-kidney transplants (SLK) has expanded from 2.2 percent in 1999 to almost 9.3 percent in 2016 [<a href="#rid30">30</a>]. This has led to concerns that some liver transplant recipients who may have reversible kidney injury are prematurely receiving kidney transplants [<a href="#rid20">20</a>].</p><p>The introduction of the new kidney allocation system in 2014 further unmasked concerns about the use of kidneys allocated as an SLK rather than as a kidney-alone transplant to ESKD patients. Because multi-organ allocation occurs before kidney-alone allocation, highly sensitized ESKD patients (with high priority in the new kidney-alone allocation system) lose the opportunity for potential kidney offers. In addition, approximately 50 percent of kidneys allocated for SLK are organs that, under kidney-alone allocation, would typically be prioritized for pediatric transplant candidates or young adults with the longest expected posttransplant survival [<a href="#rid6">6</a>]. Thus, an important goal in the evaluation of a liver transplant candidate with impaired kidney function is to determine if the patient should or should not be considered for SLK.</p><p class="headingAnchor" id="H3560343169"><span class="h3">Eligibility criteria for SLK</span><span class="headingEndMark"> — </span>From a clinical standpoint, the most important determinant of the need for SLK in patients with end-stage liver disease and kidney dysfunction is the ability to understand the nature and the anticipated course of the kidney disease after transplant. However, even though conditions such as hepatorenal syndrome and cardiorenal syndrome are usually associated with posttransplant improvement in kidney function, this is not always possible to predict. It is well recognized that protracted or recurrent episodes of AKI can cause progressive interstitial fibrosis and tubular atrophy, resulting in partial or complete non-recovery of kidney function [<a href="#rid31">31</a>], which may be potentiated in the peri- and posttransplant period by additional insults including hemodynamic stress and calcineurin inhibitor use.</p><p>As a result, until recently, the absence of standardized medical criteria has largely resulted in transplant centers arbitrarily deciding on the indication for kidney transplantation in conjunction with a non-kidney organ.</p><p>However, in 2016, the United States Organ Procurement and Transplant Network (OPTN) and United Network for Organ Sharing (UNOS) approved a new policy that formalized the allocation of SLK transplants, which went into effect in August 2017 [<a href="#rid6">6</a>]. In accordance with the new UNOS policy, liver transplant candidates who meet one of the following criteria are eligible for SLK allocation:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of CKD with a measured or calculated GFR of ≤60 mL/min for more than 90 consecutive days <strong>and</strong> at least one of the following at the time of waiting list registration:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ESKD on dialysis</p><p class="bulletIndent2"><span class="glyph">•</span>Measured or calculated creatinine clearance or GFR ≤30 mL/min</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of sustained AKI <strong>and</strong> at least one of the following, for the last six weeks:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dialysis at least once every seven days</p><p class="bulletIndent2"><span class="glyph">•</span>Measured or calculated creatinine clearance or GFR of ≤25 mL/min documented at least once every seven days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of metabolic disease, with an additional diagnosis of at least one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperoxaluria</p><p class="bulletIndent2"><span class="glyph">•</span>Atypical hemolytic uremic syndrome from mutations in factor H or factor I</p><p class="bulletIndent2"><span class="glyph">•</span>Familial non-neuropathic systemic amyloidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Methylmalonic aciduria</p><p></p><p>In addition to the above criteria defining eligibility for SLK, the new policy also includes a safety-net component to ensure that a liver transplant patient who is not initially offered SLK but who remains dialysis dependent after liver transplantation would be highly prioritized for subsequent kidney-alone offers, if both of the following conditions are met:</p><p class="bulletIndent1"><span class="glyph">●</span>The candidate is registered on the kidney waiting list between 60 and 365 days after liver transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The candidate is either on chronic dialysis <strong>or</strong> has a measured or calculated creatinine clearance or GFR of ≤20 mL/min.</p><p></p><p class="headingAnchor" id="H3722612420"><span class="h3">Role of pretransplant kidney biopsy</span><span class="headingEndMark"> — </span>The role of pretransplant kidney biopsy in liver transplant candidates is uncertain. Kidney biopsy findings are not included in the 2016 OPTN/UNOS criteria for selection of patients for SLK. Some experts propose a pre-liver transplant kidney biopsy to help make this determination.</p><p>In addition to establishing the cause of impaired kidney function, other potential benefits of kidney biopsy include the ability to determine chronicity, treatability, and likelihood of future progression or reversibility. Some have therefore suggested using the extent of glomerulosclerosis (&gt;40 percent) and interstitial fibrosis (&gt;30 percent) to guide selection of patients for SLK [<a href="#rid21">21,32,33</a>]. Although this may represent useful information regarding chronicity of kidney injury, there are few data supporting the prognostic value of kidney histology or its advantage over kidney function studies alone.</p><p>In one retrospective study, kidney biopsies were performed in 59 patients undergoing evaluation for SLK; all patients had a measured creatinine clearance of &lt;50 mL/min and/or proteinuria of &gt;500 mg/day [<a href="#rid33">33</a>]. Patients with &gt;40 percent glomerulosclerosis and/or &gt;30 percent interstitial fibrosis, or those on hemodialysis for more than two months, were recommended for SLK. Based upon these biopsy criteria, only 11 of 36 patients listed for transplant were listed for SLK, and allocation of a kidney could be avoided in 70 percent of liver transplant candidates with kidney dysfunction. Among patients who underwent liver transplantation alone, the extent of glomerulosclerosis, but not interstitial fibrosis, predicted eGFR over the first 12 months posttransplant. However, the predictive ability of kidney biopsy decreased with greater time lapse between the biopsy and liver transplant. In another retrospective study, 22 percent of liver recipients whose pretransplant kidney biopsies were deemed to show reversible histology met criteria for kidney transplantation by 12 months post-liver transplant [<a href="#rid34">34</a>]. Further studies are required to determine whether pretransplant kidney biopsies can predict long-term kidney outcomes after liver transplantation.</p><p class="headingAnchor" id="H4"><span class="h2">Approach in heart transplant candidates</span><span class="headingEndMark"> — </span>Up to one-third of all patients with New York Heart Association stage 3 or 4 end-stage heart failure have evidence of CKD [<a href="#rid35">35</a>]. Despite this, the rate of combined heart-kidney transplantation is far lower than that of simultaneous liver-kidney transplantation, with 637 combined heart-kidney transplants in the US between 2000 and 2012 [<a href="#rid36">36</a>]. Over this period, the rate of combined heart-kidney transplantation as a proportion of all heart transplants performed has increased from approximately 1.25 percent in 2000 to over 3 percent in 2011 [<a href="#rid37">37</a>]. Registry data indicate that patients receiving double-organ transplantation are more likely to be African American, diabetic, older, and have worse kidney function at the time of transplantation than patients receiving heart transplant alone [<a href="#rid37">37</a>].</p><p>Overall, the data on the evaluation of kidney function prior to orthotopic heart transplant are less well defined than in liver transplant candidates, and no formal guidelines exist. However, the following general principles may help guide the evaluation process:</p><p class="bulletIndent1"><span class="glyph">●</span>Given that the combination of kidney dysfunction and severe heart failure is common, the nature of the kidney disease, in terms of chronicity and reversibility, must be determined. Patients with a predominant picture of hemodynamically mediated AKI (cardiorenal syndrome type 1) and without obvious intrinsic kidney disease (as determined by the lack of proteinuria, normal kidney size on ultrasonography, and the absence of severe histopathology in kidney biopsy specimen) can recover sufficient native kidney function after restoration of kidney perfusion to not need subsequent kidney replacement therapy for several years. (See  <a class="medical medical_review" href="/z/d/html/13606.html" rel="external">"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/15619.html" rel="external">"Cardiorenal syndrome: Prognosis and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For heart transplant candidates with kidney dysfunction that appears to be due to irreversible kidney disease, especially those that have been dialysis dependent for a period of time (cardiorenal syndrome type 2), combined heart-kidney transplantation may be a viable option. Pretransplant kidney biopsy may be useful in determining chronicity of kidney injury, although the prognostic value of these findings, or the superiority of this approach over clinical judgment alone, is not established [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis", section on 'Heart-kidney transplantation'</a>.)</p><p></p><p>A separate issue is kidney after heart transplantation when kidney failure develops after heart transplantation. (See <a class="local">'Cardiac transplantation'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">CHRONIC KIDNEY DISEASE AFTER NON-KIDNEY ORGAN TRANSPLANTATION</span><span class="headingEndMark"> — </span>The degree of kidney function impairment posttransplant and the rate of progression of chronic kidney disease (CKD) depend to a large degree on the extent of pretransplant kidney function impairment, the nature of the organ transplanted, the intra- and early postoperative course, and the immunosuppressive regimen and individual clinical features that determine susceptibility to kidney injury. Since more than one of these factors is usually present in any given patient, some degree of CKD is present in most long-term organ recipients.</p><p class="headingAnchor" id="H7"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Calcineurin inhibitor (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) therapy remains the cornerstone of immunosuppression in most organ recipients and has been implicated as a principal cause of posttransplantation CKD [<a href="#rid38">38-57</a>]. The histopathologic characteristic of calcineurin inhibitor nephrotoxicity is similar among patients with kidney and non-kidney organ recipients. These include vascular obliteration, focal hyalinosis of small renal arteries and arterioles, global or segmental glomerulosclerosis, tubular atrophy, and striped interstitial fibrosis [<a href="#rid58">58-61</a>].A retrospective report of 105 kidney biopsies performed in a cohort of 101 bone marrow, liver, lung, and heart recipients for acute and chronic indications demonstrated histological findings of primary glomerulonephritis in 17 percent and thrombotic microangiopathy in 10 percent of patients, respectively, in addition to nonspecific chronic changes, hypertension-related damage, and calcineurin inhibitor toxicity [<a href="#rid62">62</a>]. Patients in whom either acute tubular injury or thrombotic microangiopathy predominated had the worst postbiopsy kidney outcomes. A review of calcineurin inhibitor nephrotoxicity is available in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p>Besides calcineurin inhibitor nephrotoxicity, a number of other factors predispose to decreased kidney function post-non-kidney solid organ transplant. Among the most common of these is pre-existing protracted/recurrent acute kidney injury (AKI) and/or chronic kidney damage that antedates the transplant, frequently underappreciated in the setting of organ failure pretransplant, where serum creatinine correlates poorly with actual kidney function, as discussed above (hepatorenal syndrome type 2 and cardiorenal syndrome type 2). (See  <a class="medical medical_review" href="/z/d/html/13606.html" rel="external">"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/15619.html" rel="external">"Cardiorenal syndrome: Prognosis and treatment"</a>.)</p><p>Additional posttransplant factors that contribute include specific immunosuppressive regimen (especially those containing calcineurin inhibitors or target of rapamycin [TOR] inhibitors), comorbid conditions (particularly diabetes, hypertension, and hepatitis C virus [HCV] infection), older age, type of organ transplanted (rates are higher in intestine transplant than heart transplant recipients), and surgical issues and complications including recurrent episodes of posttransplant AKI [<a href="#rid5">5</a>]. Nephropathy resulting from BK virus infection has also been reported in non-kidney organ recipients, although it is uncommon [<a href="#rid63">63-66</a>]. (See  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy"</a>.)</p><p>The best general data on underlying, independent pathogenic factors and overall incidence of CKD in non-kidney solid organ transplantation patients come from a study that described a population-based cohort of 69,321 persons who received non-kidney transplants (heart, lung, liver, and intestine) in the United States between 1990 and 2000 [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> were given to 60 and 28 percent, respectively. In this report, 11,426 patients (16.5 percent) developed stage 4 or 5 CKD (defined as a glomerular filtration rate [GFR] of 29 mL per minute per 1.73 m<sup>2</sup> of body surface area or less) during a median follow-up of 36 months. Maintenance dialysis or kidney transplantation was required in 29 percent of those who developed stage 4 or 5 CKD.</p><p>The cumulative incidence of stage 4 or 5 CKD at five years ranged from 6.9 percent among recipients of heart-lung transplants to 21.3 percent among recipients of intestine transplants. Among patients who had received liver transplants, the excess risk of CKD associated with the use of a calcineurin inhibitor was greater with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> than with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> therapy. This association was not statistically significant in recipients of heart, heart-lung, or lung transplants.</p><p class="headingAnchor" id="H8"><span class="h2">Liver transplantation</span><span class="headingEndMark"> — </span>Although immunosuppressive therapy with calcineurin inhibitors has dramatically improved patient and graft survival after orthotopic liver transplantation, the nephrotoxic effects of calcineurin inhibitors are well recognized [<a href="#rid67">67,68</a>]. Many studies have described a gradual decline in kidney function following orthotopic liver transplantation [<a href="#rid53">53,55,68-71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Using the Kidney Disease Outcomes Quality Initiative (K/DOQI) classification system, one single-center study examined the risk of CKD by stage among 230 liver recipients followed for a mean period of approximately six years [<a href="#rid4">4</a>]. Overall prevalences of CKD at 10 years were 2 percent with stage 5, 6 percent with stage 4, 57 percent with stage 3, 24 percent with stage 2, and the rest with minimal or no kidney function deficit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-center, retrospective study of 883 consecutive adult patients receiving a first liver transplant reported that 8 percent of 10-year survivors of orthotopic liver transplants had developed severe CKD (defined in this study as creatinine greater than 2.8 mg/dL [248 micromol/L]), with 50 percent of these developing end-stage kidney disease (ESKD) [<a href="#rid55">55</a>].</p><p></p><p>The presence of kidney dysfunction prior to liver transplantation is associated with decreased patient survival posttransplantation [<a href="#rid29">29,72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A group of investigators used the United Network for Organ Sharing (UNOS) database to determine the impact of pretransplant kidney function on graft and patient survival rates after liver transplantation [<a href="#rid72">72</a>]. Up to 33 percent of patients undergoing liver transplantation had some degree of kidney injury, with even mild levels of impairment (GFR of 40 to 70 mL/min) being associated with increased 30-day and two-year mortality. Creatinine clearance was the sole variable retaining posttransplant mortality predictive power in liver transplant recipients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of preoperative kidney function on outcome after liver transplant alone was assessed using the UNOS/Organ Procurement and Transplant Network (OPTN) database for the period 1999 to 2004 [<a href="#rid29">29</a>]. Compared with those with a preoperative serum creatinine concentration less than 1.0 mg/dL (88.4 micromol/L), the relative risk of death was 1.11, 1.48, 1.77, and 1.44 for those with levels between 1.0 and 2.0 mg/dL (88.4 to 176.8 micromol/L), those with levels ≥2.0 mg/dL (176.8 micromol/L), patients requiring kidney replacement therapy, and those who received a liver/kidney transplant, respectively.</p><p></p><p>Not surprisingly, the presence of impaired kidney function prior to surgery, particularly the diagnosis of hepatorenal syndrome, is a significant risk factor for posttransplantation kidney dysfunction [<a href="#rid69">69,73-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One study retrospectively examined 724 orthotopic liver transplant recipients and identified preoperative serum creatinine greater than 1.9 mg/dL, preoperative blood urea nitrogen greater than 27 mg/dL, intensive care unit (ICU) stay more than three days, and Model for End-Stage Liver Disease (MELD) score greater than 21 as important predictors of the need for kidney replacement therapy postoperatively [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the study previously discussed [<a href="#rid69">69</a>], patients who developed severe kidney failure post-liver transplant had a greater likelihood of having had hepatorenal syndrome preoperatively, when compared with those who maintained normal kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, the incidence of ESKD after liver transplantation in patients who had preoperative hepatorenal syndrome was 7 percent, compared with 2 percent in those without the syndrome [<a href="#rid74">74</a>].</p><p></p><p>On average, approximately 10 percent of patients who have hepatorenal syndrome preoperatively eventually develop ESKD [<a href="#rid69">69,74,75</a>].</p><p>Risk factors for ESKD following liver transplantation were identified using data for 43,514 recipients of deceased-donor liver transplants that were linked from the Scientific Registry of Transplant Recipients (SRTR) and the Centers for Medicare and Medicaid Services (CMS) ESKD program [<a href="#rid79">79</a>]. Donor risk factors associated with increased risk of posttransplantation ESKD included age 50 to 59 years (versus reference age 18 to 39 years) (hazard ratio [HR] 1.17, 95% CI 1.03-1.34); age 60 to 69 years (HR 1.29, 95% CI 1.10-1.51); age ≥70 years (HR 1.31, 95% CI 1.06-1.62); and donation after cardiac death (HR 1.45, 95% CI 1.17-1.80). Each hour of cold ischemia was associated with higher risk of ESKD (HR 1.02, 95% CI 1.01-1.06).</p><p>Using this data set, the following model for calculating a renal risk index (RRI) was developed:</p><p>RRI = exp [(0.00688 x recipient age-53) + (0.4292 if African American) + (-0.3725 if cholestatic) + (0.2711 if HCV) + (0.7111 if diabetes is present) + (0.2450 if BMI ≥35) + (1.2522 x ln (creatinine) if not on dialysis) + (-0.1525 x ln bilirubin/3.5) + (-0.3851 x ln (albumin/2.9) + (-0.3706 if sodium &lt;134) + (-0.2671 if status-1) + (0.4359 if previous LT) + (0.3129 if TIPSS) + (1.9097 if on dialysis)]</p><p>The calculated RRI is the risk of ESKD compared with a reference patient who is 53 years old; is not African American; does not have cholestatic disease; is hepatitis C negative; has a body mass index (BMI) &lt;35 kg/m<sup>2</sup>; does not have diabetes; has serum creatinine 1.0 mg/dL, serum albumin 2.9 g/dL, serum bilirubin 3.5 mg/dL, and serum sodium ≥134 mEq/L; is not status-1; has had no previous transplantation or transjugular intrahepatic portosystemic shunt (TIPS) procedure; and is not on dialysis.</p><p>Using 10 random cross-sections of a validation cohort, this model predicted the order of outcome among pairs of subjects approximately 75 percent of the time.</p><p>A historical analysis of the UNOS data revealed that the five-year survival in patients with a serum creatinine concentration &gt;2.0 mg/dL (177 micromol/L) was 62 and 50 percent in patients who received a combined liver-kidney transplant and liver transplant alone, respectively [<a href="#rid75">75</a>]. Additional analysis from the UNOS database suggests that kidney allograft half-life is superior with combined liver-kidney transplantation versus that associated with kidney after liver transplantation [<a href="#rid80">80</a>]. However, the findings from both of these retrospective studies were derived from registry data and, therefore, need to be cautiously interpreted. Analysis of the margin of benefit offered from combined kidney and liver transplantation must be tested in properly designed studies. Similarly, it remains to be determined whether the recently implemented simultaneous liver-kidney (SLK) allocation policy will result in improved liver transplant outcomes or what the effect will be on utilization of deceased-donor kidneys.</p><p class="headingAnchor" id="H9"><span class="h2">Pancreas transplantation</span><span class="headingEndMark"> — </span>Data on kidney function following pancreas transplantation alone, performed for diabetes mellitus, are scant. In this setting, posttransplant kidney function is principally influenced by two competing factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Beneficial effects of sustained normoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotoxic effects associated with transplantation, particularly those resulting from calcineurin inhibitors</p><p></p><p>It had been previously noted that normoglycemia following pancreas transplantation alone that persisted for five years failed to ameliorate kidney dysfunction or glomerular lesions in type 1 diabetic patients with their own kidneys [<a href="#rid81">81</a>]. The absence of observed benefit with normoglycemia was attributed to the adverse effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p>Subsequently, the relationship of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> dose and blood levels to changes in kidney function was examined in type 1 diabetic patients who underwent pancreas transplantation alone [<a href="#rid82">82</a>]. In this study, creatinine clearance decreased from 108 mL/min at baseline to 74 mL/min at five years posttransplantation in those who received pancreas transplantation, while kidney function did not change appreciably in diabetic controls. The decrement in creatinine clearance correlated with cyclosporine blood levels and dose. The investigators concluded that, among patients with type 1 diabetes mellitus who do not have kidney dysfunction and have not received a kidney transplant, pancreas transplantation does not improve kidney function. In addition, it may contribute to a significant decrement in creatinine clearance within five years after transplantation.</p><p>It was postulated that the relatively short follow-up in this study may have prevented the renoprotective effects of normoglycemia, if present, from emerging. To address this limitation, the same investigators conducted a longer, 10-year study to discern the quantitative relevance of the competing factors of normoglycemia and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> nephrotoxicity [<a href="#rid83">83</a>]. The creatinine clearance in recipients of pancreas transplants significantly declined at five years, but stabilized thereafter. Ultrastructural examination of kidney tissue from these patients revealed that the thickness of the glomerular and tubular basement membranes was similar at five years and at baseline, but had decreased by 10 years. It was concluded that pancreas transplantation can reverse the lesions of diabetic nephropathy, but reversal requires more than five years of normoglycemia [<a href="#rid83">83,84</a>].</p><p>The natural history of kidney function following pancreas transplantation alone is characterized by an initial decline in kidney function, due most likely to the untoward effect of calcineurin inhibitors. However, kidney function later stabilizes so that, when compared with a cohort of nontransplant patients with diabetes mellitus type 1, those who received a pancreas transplant have a higher creatinine clearance and less albuminuria at 10 years of follow-up.</p><p>Practically all patients listed for pancreas transplantation alone have normal or near-normal kidney function. The majority of patients with diabetes mellitus type 1 and CKD are considered for either kidney transplant alone or combined kidney and pancreas transplantation either simultaneously or sequentially. Some have proposed a calcineurin inhibitor challenge test administered pretransplant to pancreas-alone candidates to determine the degree of kidney injury induced by the immunosuppressant when deciding whether to proceed with pancreas alone, simultaneous kidney-pancreas, or kidney transplant alone, followed by subsequent pancreas transplantation [<a href="#rid85">85</a>].</p><p>Issues surrounding simultaneous kidney-pancreas transplantation, kidney followed by pancreas transplantation, and pancreas transplantation alone are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7313.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Benefits and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7305.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Patient selection and pretransplant evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1767.html" rel="external">"Pancreas and islet transplantation in diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Cardiac transplantation</span><span class="headingEndMark"> — </span>The majority of cardiac transplant recipients will develop CKD within the first year after transplant. Cardiac transplant recipients usually suffer an initial, rapid decline in kidney function in the first two years posttransplant, which is followed by a less pronounced decline afterwards [<a href="#rid45">45,48,86-97</a>]. In one study, 200 patients were followed for up to nine years post-heart transplant [<a href="#rid86">86</a>]. The average loss of GFR in the first year posttransplant was 14 mL/min, while the average loss of GFR in the subsequent eight years was 14 mL/min. Severe kidney dysfunction (GFR &lt;20 mL/min per 1.73 m<sup>2</sup>) developed in 20 percent of the patients, which was predicted by the recipient age at time of transplantation plus the GFR one year after transplantation.</p><p>The natural history of kidney function following orthotopic heart transplant was also evaluated in another report [<a href="#rid98">98</a>]. To assess the effect of heart transplantation and exposure of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> on long-term kidney function, statistical analysis was restricted to patients who survived the first year posttransplantation. Heart transplant survivors beyond the first year posttransplant have a significant decrease in kidney function over time:</p><p class="bulletIndent1"><span class="glyph">●</span>The cumulative incidence of chronic kidney failure, as defined by a GFR ≤29 mL/min per 1.73 m<sup>2</sup>, at 5, 10, and 15 years was 4.2, 10.4, and 12.5 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cumulative incidence of severe chronic kidney failure, as defined by a GFR ≤15 mL/min per 1.73 m<sup>2</sup>, at 5, 10, and 15 years was 2.1, 8.3 and 8.3 percent, respectively.</p><p></p><p>Age, pretransplantation estimated GFR (eGFR), pretransplantation diabetes, and pretransplantation hypertension were risk factors associated with a ≥10 mL/min per 1.73 m<sup>2</sup> decrement in eGFR.</p><p>Pooled weighted average serum creatinine concentrations (mg/dL) derived from published studies describing kidney function in heart transplant recipients receiving cyclosporine-based immunosuppressive therapy reveal a biphasic pattern [<a href="#rid45">45,86,89-94</a>]. During the first two years following heart transplantation, there is a steep decline in kidney function, followed by a less pronounced decline afterwards (<a class="graphic graphic_figure graphicRef58337" href="/z/d/graphic/58337.html" rel="external">figure 1</a>).</p><p>The mechanism for this biphasic pattern appears to be due to the renal response to early versus late effects. The GFR rapidly declines in the first few months after transplant, mainly as a result of exposure to perioperative and postoperative insults plus exposure to calcineurin inhibitors. Kidney function later stabilizes. In general, the GFR at one year is a better reflection of kidney functional reserve, which is also predictive of long-term kidney outcome and mortality [<a href="#rid98">98</a>]. Most studies examining calcineurin inhibitor-mediated nephrotoxicity in heart transplant patients were performed in the <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> era and may not necessarily apply to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, the calcineurin inhibitor of choice. Regardless, randomized controlled trials have demonstrated that heart recipients randomized to tacrolimus have better kidney function at 12 months posttransplant, compared with cyclosporine-treated patients [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Kidney replacement therapy</span><span class="headingEndMark"> — </span>In a report from the International Society for Heart and Lung Transplantation (ISHLT) registry, 4.4 percent of heart transplant recipients were on chronic dialysis, and 0.9 percent of patients received a kidney transplant within eight years after heart transplant [<a href="#rid100">100</a>]. Survival in patients receiving kidney transplant after heart transplant was significantly lower than for heart-only recipients at the same time points after heart transplant.</p><p>Findings related to ESKD post-heart transplantation were also reported in a study from the Canadian Organ Replacement registry [<a href="#rid101">101</a>]. The incidence of dialysis after heart transplantation was 4 percent, with survival on dialysis being significantly worse than a matched dialysis cohort. By comparison, survival was similar in those who received a kidney transplant after heart transplantation versus those in the matched dialysis cohort who had received a kidney transplant.</p><p>Similar findings as those noted from the Canadian registry were reported in a study from France. Survival among heart transplant patients who initiated dialysis was significantly lower than nonheart transplant dialysis patients [<a href="#rid102">102</a>].</p><p>Among those who require kidney replacement therapy, survival with a kidney transplant is superior to those who continue dialysis [<a href="#rid103">103,104</a>]. In a study using UNOS data, for example, the risk of death was decreased by 43 percent in patients who received a kidney transplant, compared with heart recipients maintained on dialysis [<a href="#rid103">103</a>]. Another analysis of UNOS data demonstrated that the annual number of kidney-after-heart transplants has quadrupled over the past decade [<a href="#rid105">105</a>]. Increasing dialysis duration was associated with worse outcomes after the kidney transplant, with patient death accounting for over 75 percent of kidneys that were lost. The fact that kidney quality (living versus deceased donors; standard criteria versus expanded criteria) was not a determinant of survival suggests that use of nonstandard kidneys should be readily considered in this population, rather than spending more time on the list waiting for a standard-criteria kidney.</p><p class="headingAnchor" id="H12"><span class="h2">Lung transplantation</span><span class="headingEndMark"> — </span>CKD is common following lung transplant [<a href="#rid47">47,54,57,71,106-111</a>]. The decline in kidney function is usually biphasic, with a steep decline in the first year posttransplant and a slower decline afterwards [<a href="#rid57">57</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The largest study examined kidney function in 219 patients who underwent lung or heart-lung transplantation and survived the first six months posttransplant [<a href="#rid111">111</a>]. Over one-half of the patients who survived the first posttransplant year had developed stage 3 CKD by that time [<a href="#rid112">112</a>]. During a median follow-up of 44 months, 7.3 percent of patients had developed ESKD. The cumulative incidence of doubling of the serum creatinine concentration was 34, 43, and 53 percent at one, two, and five years. However, these incidences were from basic descriptive statistics and not survival-analysis statistics, which would account for patient death. Thus, the true incidences of ESKD are much greater. Elevated diastolic blood pressure and elevated serum creatinine at one month posttransplantation were associated with poor kidney function.</p><p></p><p class="bulletIndent1">In this report, significantly less nephrotoxicity was observed with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> versus <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid111">111</a>]. The use of tacrolimus during the first six months after transplantation was associated with a significant decrease in the risk for time to doubling of serum creatinine concentration and a lower rate of acute rejection. However, these results are somewhat difficult to interpret as cyclosporine was used in an earlier era of lung transplantation, when overall results were not as good. Additional analysis of these patients found that predictors of a shorter time to doubling of the serum creatinine concentration included older age, lower GFR at one month posttransplant, and cyclosporine use during the first one-half year posttransplant [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second study also illustrated the initial steep decline in kidney function, which is followed by a less vigorous decline. In this report of 124 patients, the serum creatinine concentration at baseline, one year, and five years posttransplant was 0.8, 1.6, and 1.9 mg/dL, respectively [<a href="#rid57">57</a>].</p><p></p><p>As observed with other solid organ transplants, the tapering and withdrawal of calcineurin inhibitors can be associated with improved kidney function [<a href="#rid113">113</a>].</p><p>Among those who require kidney replacement therapy, survival with a kidney transplant is superior to those who continue dialysis. In a study from the UNOS, for example, the risk of death was decreased by 54 percent in patients who received a kidney transplant, compared with lung recipients maintained on dialysis [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Islet cell transplantation</span><span class="headingEndMark"> — </span>A paucity of data exists concerning the posttransplant effect on the kidney function of islet cell transplantation alone in patients with normal or near-normal function [<a href="#rid114">114-116</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an early report on seven patients with diabetes type 1 and normal kidney function who underwent islet transplantation with an average follow-up period of 10 months, the serum creatinine was not found to be significantly different than pretransplant serum creatinine with an average follow-up period of 10 months (1.2 and 1.3 mg/dL, respectively) [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent report elaborated on the experience with 47 patients who had diabetes type 1 and underwent islet cell transplant [<a href="#rid115">115</a>]. After an average follow-up of five years, the serum creatinine was mildly but significantly elevated when compared with pretransplant serum creatinine (1.1 and 0.9 mg/dL, respectively). Creatinine clearance nonsignificantly decreased over the course of the study period (108 to 84 mL/min at the end of follow-up). In addition, increasing proteinuria appeared to occur, with 45 percent of patients with pretransplant moderately increased albuminuria (formerly called "microalbuminuria") progressing to overt proteinuria, and 10 percent of those with no pretransplant moderately increased albuminuria progressing to overt proteinuria. In this study, patients were induced with daclizumab and subsequently maintained on <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Proteinuria in patients with clinical islet cell transplantation has been attributed to the use of sirolimus as the discontinuation of sirolimus has led to the resolution of proteinuria [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>.)</p><p></p><p>While studies on whole pancreas transplantation have shown that metabolic control in recipients with normal kidney function resulted in stabilization and reversal of diabetic lesions in the native kidney, limited data suggest that successful islet transplant may have a similar, positive impact on diabetic kidney lesions.</p><p>As an example, the effect of islet transplantation on the kidney function of 36 patients with type 1 diabetes mellitus, kidney transplants, and some degree of kidney allograft dysfunction was reported [<a href="#rid118">118</a>]. The study compared parameters of kidney function in patients with successful islet transplantation versus those who had an unsuccessful islet transplant (success was defined as fasting C-peptide levels of &gt;0.5 ng/mL for more than one year). Patients with successful islet transplant had better kidney graft survival rates at seven years when compared with those with unsuccessful islet transplant (83 versus 51 percent, respectively). Moderately increased albuminuria increased significantly in patients with an unsuccessful transplant, but did not change appreciably in those with successful islet transplant. Thus, islet transplantation, probably by partially restoring pancreatic endocrine function, not only improves the metabolic control of diabetes mellitus, but also is associated with improvements in kidney function and kidney graft life span.</p><p class="headingAnchor" id="H14"><span class="h2">Heart-lung transplantation</span><span class="headingEndMark"> — </span>Heart-lung transplantation is now an uncommon procedure that should be reserved for patients who cannot be treated by lung transplantation alone [<a href="#rid100">100</a>]. Suitable candidates include patients with severe, irreversible disease of the lung parenchyma or vasculature who also have severely compromised left ventricular function or other cardiac diseases that would preclude a successful outcome with lung transplantation alone. (See  <a class="medical medical_review" href="/z/d/html/3525.html" rel="external">"Heart-lung transplantation in adults"</a>.)</p><p>The 2005 report from the ISHLT included data on kidney function after heart-lung transplantation [<a href="#rid100">100</a>]. Within one year after transplantation, 17.8 percent of recipients developed some degree of kidney dysfunction, 3.6 percent required maintenance dialysis, and 0.4 percent received a kidney transplant [<a href="#rid100">100</a>]. Within five years, approximately 25 percent developed severe CKD, which was defined in the registry as a serum creatinine concentration &gt;2.5 mg/dL (221 micromol/L), requirement for dialysis, or a kidney transplant.</p><p>The incidence of and risk factors associated with CKD post-heart-lung transplant were also assessed in the previously cited population-based cohort study of 69,321 patients who received non-kidney transplants in the United States between 1990 and 2000, of whom 576 received a heart-lung transplant [<a href="#rid119">119</a>]. The cumulative incidence of CKD in recipients of heart-lung transplant, as defined by GFR of less than 29 mL/min per 1.73 m<sup>2</sup>, was 1.7, 4.2, and 6.9 percent at one, three, and five years, respectively.</p><p>Because these findings were nearly identical between heart transplant patients and heart-lung transplant patients, the investigators used a combined regression model for both patient groups [<a href="#rid119">119</a>]. In this model, the presence of pretransplantation kidney disease, postoperative acute kidney failure (ARF), a positive serologic test for hepatitis C prior to transplant, pretransplant diabetes, and pretransplant hypertension were all associated with increased risk of chronic kidney failure after the transplant.</p><p class="headingAnchor" id="H15"><span class="h2">Intestinal transplantation</span><span class="headingEndMark"> — </span>Although data are minimal, studies suggest that kidney function deteriorates among intestinal transplant patients [<a href="#rid120">120-123</a>]. This was best shown in a report of 10 patients (8 adults) in whom the GFR was assessed at baseline, three months posttransplantation, and yearly thereafter using chromium ethylenediaminetetraacetic acid (EDTA) clearance [<a href="#rid123">123</a>]. Among all adults, the median GFR decreased by approximately 50 percent at three months posttransplant. In addition, among the five adults with greater than one-year follow-up, the median GFR decreased by nearly 75 percent, compared with baseline levels.</p><p class="headingAnchor" id="H16"><span class="h1">PREVENTION AND TREATMENT STRATEGIES</span></p><p class="headingAnchor" id="H17"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Attenuation of the risk of nephrotoxicity posttransplantation should focus on modifiable risk factors that are common to all patients at risk of chronic kidney disease (CKD) and those that are specific to the transplant setting. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Attempts should be made to minimize perioperative and postoperative hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outside of immunosuppression by clinical indication, the use of nephrotoxic agents should be avoided. (See  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is generally advisable to achieve good control of blood pressure. In the absence of specific guidelines, general guidelines for treatment in kidney transplant recipients should be followed for non-kidney transplant recipients (see  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Hypertension'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of therapeutic modalities to attenuate the degree of proteinuria may help delay the progression of kidney failure. This includes the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as extrapolated from evidence related to nontransplant as well as kidney transplant patients with kidney dysfunction. These agents reduce the incidence and degree of proteinuria, with potential to slow the progression of kidney function impairment [<a href="#rid124">124-128</a>].</p><p></p><p class="bulletIndent1">The effectiveness of ACE inhibitors or ARBs in protecting kidney function among non-kidney organ transplant recipients with CKD is yet to be established. Until such data are available, we advise renin-angiotensin-aldosterone system (RAAS) blockade in non-kidney organ recipients who have a cardiac indication for use of these agents or in those with proteinuria. In both settings, kidney function and serum potassium levels should be carefully monitored after drug initiation and with any subsequent dose uptitration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tight control of diabetes and hyperlipidemia are important. (See  <a class="medical medical_review" href="/z/d/html/3521.html" rel="external">"Heart transplantation: Hyperlipidemia after transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Diabetes mellitus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some investigators have also suggested the use of calcium channel antagonists to counteract the hemodynamic effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> on the afferent arteriole and its effect on the glomerular filtration rate (GFR) [<a href="#rid129">129-131</a>]. Others have suggested the use of ACE inhibitors [<a href="#rid132">132</a>]. In the absence of high-quality evidence in this population to guide this decision, we advise using an ACE inhibitor (or ARB) rather than a calcium channel antagonist in patients with a cardiac indication for use of an ACE inhibitor (or ARB) and in those with proteinuria.</p><p></p><p class="headingAnchor" id="H97665951"><span class="h2">Choice of calcineurin inhibitor and calcineurin-inhibitor sparing regimens</span><span class="headingEndMark"> — </span>The choice of immunosuppression regimen, including calcineurin inhibitor, is made by the primary transplant team and is usually based on assessment of efficacy and toxicity. Cyclosporine-induced nephrotoxicity may be attenuated by dose reduction coupled with the addition of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, resulting in long-term kidney function improvement [<a href="#rid133">133</a>]. From a purely kidney function standpoint, there are now single-center case series, registry analyses, and multicenter studies demonstrating the benefit of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> over <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in both conversion and de novo settings in heart [<a href="#rid99">99,134</a>] and liver recipients [<a href="#rid5">5,135,136</a>]. Tacrolimus appears to cause less renal vasoconstriction than cyclosporine, which may in part explain the typical, short-term decrease in creatinine observed with conversion from cyclosporine [<a href="#rid137">137,138</a>].</p><p>Consistent with this notion, the vast majority of non-kidney organ recipients in the United States receive an immunosuppression regimen comprising <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, mycophenolic acid, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at the time of transplant [<a href="#rid139">139</a>]. According to the annual report of the Organ Procurement and Transplant Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR), the majority of patients remain on a tacrolimus-based regimen at one year after transplant.</p><p>A common strategy in non-kidney organ recipients has involved utilization of regimens that reduce, delay, or eliminate calcineurin inhibition. The target of rapamycin (TOR) inhibitors, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, in particular, have been used in this setting. In some non-kidney organ recipients, while the elimination or minimization of calcineurin inhibitors has been associated with a mild improvement in kidney function, this has often come at the expense of compromised immunosuppressive efficacy and worse patient outcomes [<a href="#rid140">140,141</a>]. TOR inhibitors should also be avoided in patients with estimated GFR (eGFR) &lt;40 or proteinuria as this has been shown to be associated with an accelerated progression of kidney dysfunction. Moreover, the TOR inhibitors also have significant adverse effects that have to be considered in their use (see  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>). Overall, the results of the many studies in this area have been inconsistent because of tremendous variability in study design and endpoints, patient selection, as well as duration of follow-up. There are no data on costimulation blockade for renal-sparing purposes in non-kidney organ recipients.</p><p>Ultimately, the choice of immunosuppression regimen has to be individualized to balance the overall risks and benefits of one therapy versus another.</p><p class="headingAnchor" id="H97666560"><span class="h2">Kidney transplantation for prior solid organ transplant recipients</span><span class="headingEndMark"> — </span>For non-kidney transplant recipients who develop end-stage kidney disease (ESKD), kidney transplantation results in superior survival than dialysis. This was demonstrated in one study of kidney transplant recipients who had a prior non-kidney transplant [<a href="#rid142">142</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At 141 days, the relative risk of death in patients who received a kidney transplant was the same as those on the waiting list.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond 141 days, the relative risk of death was decreased and maintained until the end of the study duration (five years).</p><p></p><p>In one study, the 10-year patient survival after kidney transplantation was 22 and 27 percent lower for recipients of a prior heart and liver transplant, respectively, compared with recipients of a kidney transplant alone [<a href="#rid142">142</a>]. The risk of death was highest among kidney transplant recipients who had received a prior lung transplant (hazard ratio 4.3, 95% CI 2.8-6.6). At five years post-kidney transplant, death with a functioning kidney allograft accounted for most graft loss in patients who had received a prior non-kidney organ transplant.</p><p>The combination of improved transplant outcomes coupled with a high prevalence of advanced CKD has led to rapid growth in the rate of being waitlisted for a subsequent kidney among prior non-kidney organ recipients deemed suitable candidates. From 1995 to 2007, the number of such patients listed for a sequential kidney following a prior non-kidney transplant increased from 72 to 975 [<a href="#rid142">142</a>].</p><p>By prior organ transplant, listing for subsequent kidney transplant increased by 330 percent among liver recipients, 307 percent among heart recipients, and 635 percent among lung recipients. This compares with 74 percent waiting-list growth for primary kidney recipients and 70 percent growth for prior kidney recipients over the same time period [<a href="#rid3">3</a>]. Because of an increased risk of death on the kidney waiting list for prior non-kidney organ recipients with advanced CKD, timely referral of medically appropriate non-kidney transplant recipients for kidney transplantation is essential [<a href="#rid142">142</a>]. Since non-kidney organ recipients fare poorly on dialysis and most will have very limited priority under the new kidney allocation system, living donation represents the best hope of transplantation for many of these patients. For this reason, we refer patients for transplant when the eGFR is between 20 to 25 mL/min per 1.73 m<sup>2</sup> in the hopes of identifying a potential donor and proceeding with preemptive kidney transplantation before their health has deteriorated to the point that they are no longer suitable kidney transplant candidates.</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease (CKD) following non-kidney solid organ transplantation is very common. Approximately 15 percent of these patients eventually develop stage 4 or 5 CKD posttransplantation. (See <a class="local">'Introduction'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The preoperative evaluation of kidney function in non-kidney solid organ transplantation candidates should focus on establishing the probability of reversibility and the chance of progression to end-stage kidney disease (ESKD). The evaluation of kidney function begins with a complete history and physical examination, an accurate measure of kidney function, a urinalysis, and kidney ultrasonography. Although kidney biopsy may be clinically indicated on occasion, there is no evidence that kidney histology is more predictive of posttransplant kidney outcomes than serum creatinine alone. Further options depend upon the particular clinical scenario and the particular non-kidney solid organ that is failing. (See <a class="local">'Evaluation of kidney function prior to non-kidney organ transplant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcineurin inhibitor therapy has been implicated as an important cause of posttransplantation CKD in non-kidney solid organ transplant recipients. An increased risk of CKD in this population is also associated with pretransplant acute kidney injury (AKI), increasing age at transplant, African-American race, female sex, pretransplantation hypertension and diabetes mellitus, type of organ transplanted, surgical issues, and/or hepatitis C infection. (See <a class="local">'Chronic kidney disease after non-kidney organ transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cumulative incidence of ESKD requiring some form of kidney replacement therapy in non-kidney solid organ transplantation ranges from 3 to 10 percent in liver transplant patients, 0 to 20 percent in heart transplant patients, 5 to 15 percent in lung transplant patients, and 3 percent in heart-lung transplant patients. There are limited data concerning islet cell and intestinal transplantation. (See <a class="local">'Chronic kidney disease after non-kidney organ transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attenuation of the risk of nephrotoxicity posttransplantation should focus on modifiable risk factors that are common to all patients at risk of CKD and those that are specific to the transplant setting. (See <a class="local">'Prevention and treatment strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For non-kidney solid organ transplant recipients with advanced CKD deemed healthy enough to potentially receive a subsequent kidney transplant, the risk of dying or being delisted while awaiting a kidney is markedly elevated. We recommend the timely referral of medically appropriate patients for kidney transplantation, early discussion about live-donor kidney transplantation, and low threshold to recommend use of nonstandard-criteria deceased-donor kidneys. (See <a class="local">'Overview'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller BW. Chronic kidney disease in solid-organ transplantation. Adv Chronic Kidney Dis 2006; 13:29.</a></li><li><a class="nounderline abstract_t">Chandrakantan A, de Mattos AM, Naftel D, et al. Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. Clin J Am Soc Nephrol 2006; 1:832.</a></li><li><a class="nounderline abstract_t">Srinivas TR, Stephany BR, Budev M, et al. An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. Clin J Am Soc Nephrol 2010; 5:1881.</a></li><li><a class="nounderline abstract_t">O'Riordan A, Wong V, McCormick PA, et al. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21:2630.</a></li><li><a class="nounderline abstract_t">Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.</a></li><li><a class="nounderline abstract_t">Formica RN, Aeder M, Boyle G, et al. Simultaneous Liver-Kidney Allocation Policy: A Proposal to Optimize Appropriate Utilization of Scarce Resources. Am J Transplant 2016; 16:758.</a></li><li><a class="nounderline abstract_t">Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18:3031.</a></li><li><a class="nounderline abstract_t">Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10:301.</a></li><li><a class="nounderline abstract_t">Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.</a></li><li><a class="nounderline abstract_t">Shaffi K, Uhlig K, Perrone RD, et al. Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis 2014; 63:1007.</a></li><li><a class="nounderline abstract_t">Tanriover B, Mejia A, Weinstein J, et al. Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era. Transplantation 2008; 86:1548.</a></li><li><a class="nounderline abstract_t">Skluzacek PA, Szewc RG, Nolan CR 3rd, et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42:1169.</a></li><li><a class="nounderline abstract_t">Francoz C, Nadim MK, Baron A, et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 2014; 59:1514.</a></li><li><a class="nounderline abstract_t">Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005; 20:1617.</a></li><li><a class="nounderline abstract_t">Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48:850.</a></li><li><a class="nounderline abstract_t">Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005; 11:344.</a></li><li><a class="nounderline abstract_t">Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102:173.</a></li><li><a class="nounderline abstract_t">Xirouchakis E, Marelli L, Cholongitas E, et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011; 6:84.</a></li><li><a class="nounderline abstract_t">De Souza V, Hadj-Aissa A, Dolomanova O, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014; 59:1522.</a></li><li><a class="nounderline abstract_t">Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7:1702.</a></li><li><a class="nounderline abstract_t">Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002; 8:193.</a></li><li><a class="nounderline abstract_t">Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8:91.</a></li><li><a class="nounderline abstract_t">Wadei HM, Geiger XJ, Cortese C, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8:2618.</a></li><li><a class="nounderline abstract_t">Thompson BC, Kingdon E, Johnston M, et al. Transjugular kidney biopsy. Am J Kidney Dis 2004; 43:651.</a></li><li><a class="nounderline abstract_t">Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37:1144.</a></li><li><a class="nounderline abstract_t">Sam R, Chebrolu SB, Reyes CV, et al. Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation. Clin Nephrol 2003; 60:53.</a></li><li><a class="nounderline abstract_t">Labban B, Arora N, Restaino S, et al. The role of kidney biopsy in heart transplant candidates with kidney disease. Transplantation 2010; 89:887.</a></li><li><a class="nounderline abstract_t">McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.</a></li><li><a class="nounderline abstract_t">Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6:2651.</a></li><li class="breakAll">https://unos.org/data/transplant-trends/#transplants_by_organ_type+year+2016 (Accessed on November 06, 2018).</li><li><a class="nounderline abstract_t">Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression. J Am Soc Nephrol 2015; 26:1765.</a></li><li><a class="nounderline abstract_t">Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther 2005; 21:949.</a></li><li><a class="nounderline abstract_t">Pichler RH, Huskey J, Kowalewska J, et al. Kidney Biopsies May Help Predict Renal Function After Liver Transplantation. Transplantation 2016; 100:2122.</a></li><li><a class="nounderline abstract_t">Wadei HM, Heckman MG, Rawal B, et al. Renal outcomes of liver transplant recipients who had pretransplant kidney biopsy. Transplantation 2014; 98:1323.</a></li><li><a class="nounderline abstract_t">McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004.</a></li><li><a class="nounderline abstract_t">Schaffer JM, Chiu P, Singh SK, et al. Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure. Am J Transplant 2014; 14:384.</a></li><li><a class="nounderline abstract_t">Karamlou T, Welke KF, McMullan DM, et al. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: Analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database. J Thorac Cardiovasc Surg 2014; 147:456.</a></li><li><a class="nounderline abstract_t">Devineni R, McKenzie N, Keown P, et al. Cyclosporine in cardiac transplantation. Can J Surg 1984; 27:252.</a></li><li><a class="nounderline abstract_t">Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34:515.</a></li><li><a class="nounderline abstract_t">Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50:1089.</a></li><li><a class="nounderline abstract_t">Van Buren DH, Burke JF, Lewis RM. Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 1994; 4:S17.</a></li><li><a class="nounderline abstract_t">El Kossi MM, Ibrahim A, Lock TJ, El Nahas AM. Impact of cardiac transplantation on kidney function: a single- center experience. Transplant Proc 2003; 35:1527.</a></li><li><a class="nounderline abstract_t">van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998; 13:2322.</a></li><li><a class="nounderline abstract_t">Waser M, Maggiorini M, Binswanger U, et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12:846.</a></li><li><a class="nounderline abstract_t">Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up. Transplantation 1990; 50:589.</a></li><li><a class="nounderline abstract_t">Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63:664.</a></li><li><a class="nounderline abstract_t">Zaltzman JS, Pei Y, Maurer J, et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54:875.</a></li><li><a class="nounderline abstract_t">Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9:12.</a></li><li><a class="nounderline abstract_t">McKenzie N, Keown P, Stiller C, et al. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985; 4:400.</a></li><li><a class="nounderline abstract_t">Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35:2307.</a></li><li><a class="nounderline abstract_t">Lynn M, Abreo K, Zibari G, McDonald J. End-stage renal disease in liver transplants. Clin Transplant 2001; 15 Suppl 6:66.</a></li><li><a class="nounderline abstract_t">Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int 1994; 7 Suppl 1:S52.</a></li><li><a class="nounderline abstract_t">Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170.</a></li><li><a class="nounderline abstract_t">Pattison JM, Petersen J, Kuo P, et al. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26:643.</a></li><li><a class="nounderline abstract_t">Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66:59.</a></li><li><a class="nounderline abstract_t">Sehgal V, Radhakrishnan J, Appel GB, et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26:193.</a></li><li><a class="nounderline abstract_t">Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10:1136.</a></li><li><a class="nounderline abstract_t">Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30:964.</a></li><li><a class="nounderline abstract_t">Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10:296.</a></li><li><a class="nounderline abstract_t">Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40:243.</a></li><li><a class="nounderline abstract_t">Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311:699.</a></li><li><a class="nounderline abstract_t">Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10:2017.</a></li><li><a class="nounderline abstract_t">Barton TD, Blumberg EA, Doyle A, et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis 2006; 8:102.</a></li><li><a class="nounderline abstract_t">Schmid H, Burg M, Kretzler M, et al. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 2005; 5:1562.</a></li><li><a class="nounderline abstract_t">Limaye AP, Smith KD, Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5:614.</a></li><li><a class="nounderline abstract_t">Barber CE, Hewlett TJ, Geldenhuys L, et al. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8:113.</a></li><li><a class="nounderline abstract_t">Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490.</a></li><li><a class="nounderline abstract_t">U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110.</a></li><li><a class="nounderline abstract_t">Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72:1934.</a></li><li><a class="nounderline abstract_t">Iwatsuki S, Esquivel CO, Klintmalm GB, et al. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc 1985; 17:191.</a></li><li><a class="nounderline abstract_t">de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.</a></li><li><a class="nounderline abstract_t">Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35:1179.</a></li><li><a class="nounderline abstract_t">Sanchez EQ, Gonwa TA, Levy MF, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78:1048.</a></li><li><a class="nounderline abstract_t">Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59:361.</a></li><li><a class="nounderline abstract_t">Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64:1760.</a></li><li><a class="nounderline abstract_t">Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21:478.</a></li><li><a class="nounderline abstract_t">Cabezuelo JB, Ramírez P, Ríos A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69:1073.</a></li><li><a class="nounderline abstract_t">O'Riordan A, Wong V, McQuillan R, et al. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007; 7:168.</a></li><li><a class="nounderline abstract_t">Sharma P, Goodrich NP, Schaubel DE, et al. Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol 2013; 24:2045.</a></li><li><a class="nounderline abstract_t">Simpson N, Cho YW, Cicciarelli JC, et al. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation 2006; 82:1298.</a></li><li><a class="nounderline abstract_t">Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342:1193.</a></li><li><a class="nounderline abstract_t">Fioretto P, Steffes MW, Mihatsch MJ, et al. Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995; 48:489.</a></li><li><a class="nounderline abstract_t">Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.</a></li><li><a class="nounderline abstract_t">Fioretto P, Kim Y, Mauer M. Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens 1998; 7:489.</a></li><li><a class="nounderline abstract_t">Brennan DC, Stratta RJ, Lowell JA, et al. Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation. Transplantation 1994; 57:1606.</a></li><li><a class="nounderline abstract_t">Lindelöw B, Bergh CH, Herlitz H, Waagstein F. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11:951.</a></li><li><a class="nounderline abstract_t">Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:549.</a></li><li><a class="nounderline abstract_t">Radovancevic B, Birovljev S, Frazier OH, et al. Long-term follow-up of cyclosporine-treated cardiac transplant recipients. Transplant Proc 1990; 22:21.</a></li><li><a class="nounderline abstract_t">Herlitz H, Lindelöw B. Renal failure following cardiac transplantation. Nephrol Dial Transplant 2000; 15:311.</a></li><li><a class="nounderline abstract_t">Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10:63.</a></li><li><a class="nounderline abstract_t">Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992; 11:926.</a></li><li><a class="nounderline abstract_t">Zietse R, Balk AH, vd Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14:1.</a></li><li><a class="nounderline abstract_t">Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11:1.</a></li><li><a class="nounderline abstract_t">Goral S, Ynares C, Shyr Y, et al. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997; 16:1106.</a></li><li><a class="nounderline abstract_t">Cirillo M, De Santo LS, Pollastro RM, et al. Creatinine clearance and hemoglobin concentration before and after heart transplantation. Semin Nephrol 2005; 25:413.</a></li><li><a class="nounderline abstract_t">Arora S, Andreassen A, Simonsen S, et al. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007; 84:149.</a></li><li><a class="nounderline abstract_t">Deuse T, Haddad F, Pham M, et al. Twenty-year survivors of heart transplantation at Stanford University. Am J Transplant 2008; 8:1769.</a></li><li><a class="nounderline abstract_t">Al Aly Z, Abbas S, Moore E, et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 2005; 19:683.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.</a></li><li><a class="nounderline abstract_t">Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005. J Heart Lung Transplant 2005; 24:945.</a></li><li><a class="nounderline abstract_t">Alam A, Badovinac K, Ivis F, et al. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007; 7:461.</a></li><li><a class="nounderline abstract_t">Villar E, Boissonnat P, Sebbag L, et al. Poor prognosis of heart transplant patients with end-stage renal failure. Nephrol Dial Transplant 2007; 22:1383.</a></li><li><a class="nounderline abstract_t">Lonze BE, Warren DS, Stewart ZA, et al. Kidney transplantation in previous heart or lung recipients. Am J Transplant 2009; 9:578.</a></li><li><a class="nounderline abstract_t">Gill J, Shah T, Hristea I, et al. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant 2009; 9:844.</a></li><li><a class="nounderline abstract_t">Cassuto JR, Reese PP, Bloom RD, et al. Kidney transplantation in patients with a prior heart transplant. Transplantation 2010; 89:427.</a></li><li><a class="nounderline abstract_t">Broekroelofs J, Stegeman CA, Navis G, de Jong PE. Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 1999; 14:1841.</a></li><li><a class="nounderline abstract_t">Maurer JR, Tewari S. Nonpulmonary medical complications in the intermediate and long-term survivor. Clin Chest Med 1997; 18:367.</a></li><li><a class="nounderline abstract_t">Broekroelofs J, Navis GJ, Stegeman CA, et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation 2000; 69:1624.</a></li><li><a class="nounderline abstract_t">Navis G, Broekroelofs J, Mannes GP, et al. Renal hemodynamics after lung transplantation. A prospective study. Transplantation 1996; 61:1600.</a></li><li><a class="nounderline abstract_t">Tsimaratos M, Viard L, Kreitmann B, et al. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 2000; 69:2055.</a></li><li><a class="nounderline abstract_t">Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61:2228.</a></li><li><a class="nounderline abstract_t">Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006; 6:2157.</a></li><li><a class="nounderline abstract_t">Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81:355.</a></li><li><a class="nounderline abstract_t">Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230.</a></li><li><a class="nounderline abstract_t">Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060.</a></li><li><a class="nounderline abstract_t">Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007; 7:91.</a></li><li><a class="nounderline abstract_t">Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5:2318.</a></li><li><a class="nounderline abstract_t">Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14:2150.</a></li><li><a class="nounderline abstract_t">Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6:671.</a></li><li><a class="nounderline abstract_t">Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 2005; 242:480.</a></li><li><a class="nounderline abstract_t">Ueno T, Kato T, Gaynor J, et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. Transplant Proc 2006; 38:1762.</a></li><li><a class="nounderline abstract_t">Ueno T, Kato T, Gaynor J, et al. Renal function after pediatric intestinal transplant. Transplant Proc 2006; 38:1759.</a></li><li><a class="nounderline abstract_t">Herlenius G, Fägerlind M, Krantz M, et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. Transplantation 2008; 86:108.</a></li><li><a class="nounderline abstract_t">Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58.</a></li><li><a class="nounderline abstract_t">Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862.</a></li><li><a class="nounderline abstract_t">Borchhardt K, Haas N, Yilmaz N, et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52:1622.</a></li><li><a class="nounderline abstract_t">Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55:1309.</a></li><li><a class="nounderline abstract_t">Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38:873.</a></li><li><a class="nounderline abstract_t">Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant 1992; 11:1194.</a></li><li><a class="nounderline abstract_t">Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63:1435.</a></li><li><a class="nounderline abstract_t">Fassi A, Sangalli F, Colombi F, et al. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis 1999; 33:267.</a></li><li><a class="nounderline abstract_t">Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Transplant 1991; 10:373.</a></li><li><a class="nounderline abstract_t">Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36:2823.</a></li><li><a class="nounderline abstract_t">Israni A, Brozena S, Pankewycz O, et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39:E16.</a></li><li><a class="nounderline abstract_t">Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938.</a></li><li><a class="nounderline abstract_t">Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5:1111.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77:1457.</a></li><li><a class="nounderline abstract_t">Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732.</a></li><li><a class="nounderline abstract_t">Annual Data Report of the US Organ Procurement and Transplantation Network. Preface. Am J Transplant 2014; 14 Suppl 1:5.</a></li><li><a class="nounderline abstract_t">De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12:3008.</a></li><li><a class="nounderline abstract_t">Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14:356.</a></li><li><a class="nounderline abstract_t">Cassuto JR, Reese PP, Sonnad S, et al. Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients. Am J Transplant 2010; 10:2502.</a></li></ol></div><div id="topicVersionRevision">Topic 7331 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic kidney disease in solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699294" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813856" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735393" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chronic kidney disease post-liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954741" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic renal failure after transplantation of a nonrenal organ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603142" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Simultaneous Liver-Kidney Allocation Policy: A Proposal to Optimize Appropriate Utilization of Scarce Resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039925" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic kidney disease after nonrenal solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762871" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185192" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The evaluation of renal function and disease in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703720" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077888" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655188" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prediction of GFR in liver transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037821" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855207" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12029000" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719405" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982481" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829419" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123197" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532752" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Simultaneous liver-kidney transplantation: evaluation to decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11910564" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Identification of patients best suited for combined liver-kidney transplantation: part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11862584" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032225" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042542" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transjugular kidney biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11382682" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transjugular renal biopsy in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872859" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220572" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The role of kidney biopsy in heart transplant candidates with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702589" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939515" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939515" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810494" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15813830" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Review article: current management of renal dysfunction in the cirrhotic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27479161" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kidney Biopsies May Help Predict Renal Function After Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24914572" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal outcomes of liver transplant recipients who had pretransplant kidney biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769700" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24279876" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183335" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: Analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6232993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cyclosporine in cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937936" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Insights into chronic cyclosporine nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887265" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193290" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Renal function in patients receiving long-term cyclosporine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12826212" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of cardiac transplantation on kidney function: a single- center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761516" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Renal insufficiency after heart transplantation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8241226" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2219280" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1440856" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cyclosporine nephrotoxicity in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3544821" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3916514" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of cyclosporine on renal function following orthotopic heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14529923" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903391" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : End-stage renal disease in liver transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11271297" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7518975" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573020" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The incidence of renal failure in one hundred consecutive heart-lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679823" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Chronic renal failure following liver transplantation: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611252" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232701" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Renal failure in the recipients of nonrenal solid organ transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546916" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cyclosporine nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240057" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The spectrum of ciclosporin nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942772" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6382005" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cyclosporine-associated chronic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883535" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734633" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888070" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : BK virus associated nephropathy in native kidneys of a heart allograft recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707418" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Polyomavirus nephropathy in native kidneys of non-renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734635" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : BK virus nephropathy in a heart transplant recipient: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998647" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7523946" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773892" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3895661" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nephrotoxicity of cyclosporine in liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676738" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981768" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480173" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7871566" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impact of pretransplant renal function on survival after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9422417" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249201" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The course of type 1 hepato-renal syndrome post liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528257" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk factors of acute renal failure after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109735" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029423" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Patient-specific prediction of ESRD after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130778" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7901527" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564117" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654536" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Reversal of lesions of diabetic nephropathy after pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818194" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diabetic nephropathy as a model of reversibility of established renal lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8009595" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770975" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Predictors and evolution of renal function during 9 years following heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8369318" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349735" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term follow-up of cyclosporine-treated cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10692514" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Renal failure following cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007172" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420240" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017475" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Time course of the decline in renal function in cyclosporine-treated heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067686" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402509" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term renal function in heart transplant recipients receiving cyclosporine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298265" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Creatinine clearance and hemoglobin concentration before and after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667805" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557718" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Twenty-year survivors of heart transplantation at Stanford University.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16146562" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The natural history of renal function following orthotopic heart transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686761" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102427" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283490" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267535" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Poor prognosis of heart transplant patients with end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260837" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Kidney transplantation in previous heart or lung recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344470" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177344" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Kidney transplantation in patients with a prior heart transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462257" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187828" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nonpulmonary medical complications in the intermediate and long-term survivor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10836372" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8669104" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Renal hemodynamics after lung transplantation. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852596" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12028464" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Predictors of renal function following lung or heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827787" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477220" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10911004" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983207" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Five-year follow-up after clinical islet transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227560" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Changes in renal function after clinical islet transplantation: four-year observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095517" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874470" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539623" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Kidney disease after heart and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192808" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : 100 multivisceral transplants at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908274" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908273" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Renal function after pediatric intestinal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622286" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Chronic kidney disease--a common and serious complication after intestinal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620545" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082500" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9407509" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8390733" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The effects of lisinopril on renal function in proteinuric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2148357" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457446" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175807" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023637" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854764" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15621159" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877596" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326428" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816894" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167607" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Oral cyclosporine but not tacrolimus reduces renal transplant blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907418" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373164" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Annual Data Report of the US Organ Procurement and Transplantation Network. Preface.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882750" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24456026" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977641" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
